Masthead
 

Custom Search
ADVERTISEMENT
Today's Health Photos
BARCELONA (Reuters) - Sales forecasts for Novartis's new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease.

BARCELONA (Reuters) - A nerve stimulation device from Cyberonics improved cardiac function in heart failure patients in a small clinical trial, in contrast to an unsuccessful study backed by Boston Scientific.

STOCKHOLM (Reuters) - A hospital in the Swedish capital is investigating a possible case of Ebola, Swedish media reported on Sunday.

BARCELONA (Reuters) - The expected launch of Novartis's new heart failure drug next year promises to be the company's most exciting ever and profit margins on the medicine will be good, its head of pharmaceuticals said on Sunday.

BARCELONA (Reuters) - A major clinical study has raised concerns about a drug from private French company Servier that helps lower the heart rate and which was licensed to U.S. group Amgen last year.

BARCELONA (Reuters) - An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.

BARCELONA (Reuters) - Swiss engineers, famous for making the world's finest watches, are turning their hands to cardiology with a prototype battery-less pacemaker based on a self-winding wristwatch.

MONROVIA/CONAKRY (Reuters) - Crowds sang and danced in the streets of a seaside neighborhood in Liberia on Saturday as the government lifted quarantine measures designed to contain the spread of the deadly Ebola virus.

BARCELONA (Reuters) - A new medicine from Novartis could replace drugs that have been central to treating heart failure for a quarter of century, after proving remarkably effective in reducing deaths in a keenly awaited study.

BARCELONA (Reuters) - A Boston Scientific device that stimulates the vagus nerve – a superhighway connecting the brain to the rest of the body - failed to help patients with heart failure in a mid-stage clinical trial.

ADVERTISEMENT
Log into your Thames Valley Portal
Video
loading